Wockhardt Limited has been in focus on Tuesday. On December 17, 2024, Wockhardt share price (NSE: WOCKPHARMA) opened at ₹1,521.30, down from its previous close of ₹1,531.10. At 10:17 AM, the share price of Wockhardt was trading at ₹1,505.00, down by 1.70% on the NSE.
Notably, the company’s share price touched its 52-week high on December 16, 2024, at ₹1,536.60. This was after the company announced a successful liver transplant for a U.S. cancer patient. The procedure was made possible through Zaynich™ (Zidebactam/Cefepime, WCK 5222), which effectively eradicated dual extreme-drug-resistant Gram-negative pathogens, enabling the patient to resume chemotherapy.
Zaynich™, a novel antibiotic from Wockhardt combining Zidebactam and Cefepime, targets multi-drug-resistant Gram-negative infections. The drug is nearing the completion of its Phase III clinical study, which will pave the way for its global registration and marketing authorisation.
The company reported a 7% QoQ growth in revenue for Q2FY25, totalling ₹818 crore, up from ₹762 crore in the previous quarter. EBITDA increased by 71% QoQ, reaching ₹139 crore compared to ₹81 crore last year.
For H1FY25, revenue grew by 10% YoY, reaching ₹1,565 crore, up from ₹1,420 crore in H1FY24. EBITDA for H1FY25 saw a 112% YoY increase, totalling ₹239 crore, compared to ₹113 crore in the previous year.
Wockhardt is a global pharmaceutical and biotech company focused on research. Its New Drug Discovery program targets the critical need for anti-bacterial drugs to combat the growing issue of superbugs resistant to treatment.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
Published on: Dec 17, 2024, 1:01 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates